HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
121,477,941
Share change
+6,740,862
Total reported value
$1,555,798,486
Put/Call ratio
12%
Price per share
$12.82
Number of holders
161
Value change
+$86,238,127
Number of buys
97
Number of sells
55

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2017

As of 30 Jun 2017, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 161 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 121,477,941 shares. The largest 10 holders included Third Security, LLC, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, BB BIOTECH AG, First Eagle Investment Management, LLC, FMR LLC, Invesco Ltd., SENZAR ASSET MANAGEMENT, LLC, and STATE STREET CORP. This page lists 161 institutional shareholders reporting positions in this security for the Q2 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.